These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 28444691)

  • 1. MALDI-MS profiling of serum O-glycosylation and N-glycosylation in COG5-CDG.
    Palmigiano A; Bua RO; Barone R; Rymen D; Régal L; Deconinck N; Dionisi-Vici C; Fung CW; Garozzo D; Jaeken J; Sturiale L
    J Mass Spectrom; 2017 Jun; 52(6):372-377. PubMed ID: 28444691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis.
    Yen-Nicolaÿ S; Boursier C; Rio M; Lefeber DJ; Pilon A; Seta N; Bruneel A
    Proteomics Clin Appl; 2015 Aug; 9(7-8):787-93. PubMed ID: 25641685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein C-III O-glycoform profiling of 500 serum samples by matrix-assisted laser desorption/ionization mass spectrometry for diagnosis of congenital disorders of glycosylation.
    Wada Y; Okamoto N
    J Mass Spectrom; 2021 Apr; 56(4):e4597. PubMed ID: 32677746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II.
    Guillard M; Morava E; van Delft FL; Hague R; Körner C; Adamowicz M; Wevers RA; Lefeber DJ
    Clin Chem; 2011 Apr; 57(4):593-602. PubMed ID: 21273509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation.
    Xia B; Zhang W; Li X; Jiang R; Harper T; Liu R; Cummings RD; He M
    Anal Biochem; 2013 Nov; 442(2):178-85. PubMed ID: 23928051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometry glycophenotype characterization of ALG2-CDG in Argentinean patients with a new genetic variant in homozygosis.
    Papazoglu GM; Cubilla M; Pereyra M; de Kremer RD; Pérez B; Sturiale L; Asteggiano CG
    Glycoconj J; 2021 Apr; 38(2):191-200. PubMed ID: 33644825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative quantification of plasma N-glycans in type II congenital disorder of glycosylation patients by mass spectrometry.
    Barbosa EA; Fontes NDC; Santos SCL; Lefeber DJ; Bloch C; Brum JM; Brand GD
    Clin Chim Acta; 2019 May; 492():102-113. PubMed ID: 30776362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALG12-CDG: novel glycophenotype insights endorse the molecular defect.
    Sturiale L; Bianca S; Garozzo D; Terracciano A; Agolini E; Messina A; Palmigiano A; Esposito F; Barone C; Novelli A; Fiumara A; Jaeken J; Barone R
    Glycoconj J; 2019 Dec; 36(6):461-472. PubMed ID: 31529350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylation Analysis for Congenital Disorders of Glycosylation.
    Li X; Raihan MA; Reynoso FJ; He M
    Curr Protoc Hum Genet; 2015 Jul; 86():17.18.1-17.18.22. PubMed ID: 26132001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency in COG5 causes a moderate form of congenital disorders of glycosylation.
    Paesold-Burda P; Maag C; Troxler H; Foulquier F; Kleinert P; Schnabel S; Baumgartner M; Hennet T
    Hum Mol Genet; 2009 Nov; 18(22):4350-6. PubMed ID: 19690088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COG5-CDG: expanding the clinical spectrum.
    Rymen D; Keldermans L; Race V; Régal L; Deconinck N; Dionisi-Vici C; Fung CW; Sturiale L; Rosnoblet C; Foulquier F; Matthijs G; Jaeken J
    Orphanet J Rare Dis; 2012 Dec; 7():94. PubMed ID: 23228021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, molecular and glycophenotype insights in SLC39A8-CDG.
    Bonaventura E; Barone R; Sturiale L; Pasquariello R; Alessandrì MG; Pinto AM; Renieri A; Panteghini C; Garavaglia B; Cioni G; Battini R
    Orphanet J Rare Dis; 2021 Jul; 16(1):307. PubMed ID: 34246313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry of transferrin glycoforms to detect congenital disorders of glycosylation: Site-specific profiles and pitfalls.
    Wada Y
    Proteomics; 2016 Dec; 16(24):3105-3110. PubMed ID: 27095603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with unsolved congenital disorders of glycosylation type II can be subdivided in six distinct biochemical groups.
    Wopereis S; Morava E; Grünewald S; Adamowicz M; Huijben KM; Lefeber DJ; Wevers RA
    Glycobiology; 2005 Dec; 15(12):1312-9. PubMed ID: 16037491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HILIC-UPLC-MS for high throughput and isomeric N-glycan separation and characterization in Congenital Disorders Glycosylation and human diseases.
    Messina A; Palmigiano A; Esposito F; Fiumara A; Bordugo A; Barone R; Sturiale L; Jaeken J; Garozzo D
    Glycoconj J; 2021 Apr; 38(2):201-211. PubMed ID: 32915358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry of transferrin and apolipoprotein C-III for diagnosis and screening of congenital disorder of glycosylation.
    Wada Y
    Glycoconj J; 2016 Jun; 33(3):297-307. PubMed ID: 26873821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biochemical presentation of siblings with COG-7 deficiency, a lethal multiple O- and N-glycosylation disorder.
    Spaapen LJ; Bakker JA; van der Meer SB; Sijstermans HJ; Steet RA; Wevers RA; Jaeken J
    J Inherit Metab Dis; 2005; 28(5):707-14. PubMed ID: 16151902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fetal glycosylation defect due to ALG3 and COG5 variants detected via amniocentesis: Complex glycosylation defect with embryonic lethal phenotype.
    Ferrer A; Starosta RT; Ranatunga W; Ungar D; Kozicz T; Klee E; Rust LM; Wick M; Morava E
    Mol Genet Metab; 2020 Dec; 131(4):424-429. PubMed ID: 33187827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global serum glycoform profiling for the investigation of dystroglycanopathies & Congenital Disorders of Glycosylation.
    Heywood WE; Bliss E; Mills P; Yuzugulen J; Carreno G; Clayton PT; Muntoni F; Worthington VC; Torelli S; Sebire NJ; Mills K; Grunewald S
    Mol Genet Metab Rep; 2016 Jun; 7():55-62. PubMed ID: 27134828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation.
    Sturiale L; Barone R; Garozzo D
    J Inherit Metab Dis; 2011 Aug; 34(4):891-9. PubMed ID: 21384227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.